• CENTRE FOR COMMERCIALIZATION OF CANCER IMMUNOTHERAPY - C3I



Clinical Research Unit

C3i benefits from the well-established Hôpital Maisonneuve-Rosemont (HMR) clinical research unit (CRU) infrastructure, under the leadership of Dr Luigina Mollica, which includes:

  • Largest group of principal investigators in the field of hemato-oncology in Québec (26).
  • Recognized key opinion leaders (KOL) in most tumor sites
  • The network of the CML-MPN Quebec Research Group which regroups hematologists from 20 oncology centers of the province of Québec.
  • Expertise in registries and real-world evidence studies
  • Networking with other Canadian groups, namely
    • the National Cancer Institute of Canada (NCIC)
    • The Canadian Blood and Marrow Transplant Group (CBMTG).
  • Direct links with the GMP manufacturing and the Biomarker and Diagnostic units.
  • Expertise in conducting Chimeric Antigen Receptor (CAR) T-cell and immune check-point inhibitors clinical trials

The CRU offers in-house expertise in all phases of clinical trial development and implementation, including Phase I and IV, as well as in regulatory affairs, including submissions to Health Canada, and in-person interactions with Health Canada. The existing team is currently involved in more than 60 active clinical trials in hematology-oncology trials and also participate in cancer immunotherapy trials.


C3i can leverage the CRU services to establish co-development alliances with biotechnology, pharmaceutical and academic partners. Our goal is to accelerate development of new treatment paradigms and proof-of-concepts and as well as confirmatory trials for new medications and new therapeutic indications for existing medications.

The mission of C3i is to provide a comprehensive expertise for cancer-immunotherapy trials and unmatched performance. C3i intends to leverage the CRU to become the leading CRO in Cancer Immunotherapy for Canada and abroad.